Haplogen Pharmaceuticals: Clinical trial application for the new drug HBM7575/SKB575 for the treatment of atopic dermatitis developed in collaboration with Corbus Pharmaceuticals has been approved.

On March 9th, Hengbo Pharmaceutical and Corvidia announced that the new drug clinical trial application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin and an undisclosed target developed through their collaboration, has been approved by the Chinese National Medical Products Administration for the treatment of atopic dermatitis.